## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.1% below STRENGTH zone (4.0-10.0%); PEG 1.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.24)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Hologic stock hits 52-week high at $75.14 By Investing.com**
- Source: Investing.com Australia | 20251215T150019 | Bullish | Relevance: 100%
- Hologic Inc (HOLX) stock recently hit a 52-week high of $75.14, marking a 3.67% increase over the past year. The medical technology company demonstrates strong financial health with moderate debt, an impressive Altman Z-Score, and low price volatility, trading slightly below its Fair Value according to InvestingPro. Recent news also highlights strong Q4 2025 results, expanded CE marking for its Genius Digital Diagnostics System in the EU, and upcoming presentations on its Breast Cancer Index Test.

**2. Hologic's BCI test shows growing impact in endocrine therapy decisions**
- Source: MSN | 20251214T091945 | Bullish | Relevance: 100%
- The article highlights the increasing influence of Hologic's Breast Cancer Index (BCI) test on endocrine therapy decisions. This suggests that the BCI test is gaining recognition as a valuable tool for guiding treatment strategies in breast cancer patients.

**3. Is Hologic Stock Outperforming the Nasdaq?**
- Source: Palmetto Grain Brokerage | 20251212T140757 | Somewhat-Bullish | Relevance: 100%
- Hologic, Inc. (HOLX) is a large-cap medical instruments & supplies company whose stock has recently outperformed the Nasdaq Composite. Despite some grim long-term performance, Hologic's Q3 results exceeded expectations, driven by strong revenue growth and increased non-GAAP operating margins. The stock shows a bullish trend, trading above its 50-day and 200-day moving averages, and analysts currently rate it a "Hold" with modest upside potential.

**4. Is Hologic Stock Outperforming the Nasdaq?**
- Source: Markets Financial Content | 20251212T040400 | Somewhat-Bullish | Relevance: 100%
- Hologic, Inc. (HOLX) has demonstrated a mixed performance compared to the Nasdaq Composite. While HOLX stock soared 12.7% over the past three months, outpacing the Nasdaq's 7% gains, its longer-term performance shows a 3.8% gain year-to-date and a 93 bps dip over 52 weeks, lagging the Nasdaq significantly. Despite these long-term challenges, Hologic beat Q3 revenue and EPS expectations, and analysts currently rate the stock as a "Hold" with a modest upside potential.

**5. Edge-GPU Breast Tomosynthesis Box Market Intelligence 2025-2029 Featuring Hologic, GE Healthcare Technologies, Fujifilm, Canon Medical Systems, Philips and More - ResearchAndMarkets.com**
- Source: Business Wire | 20251211T120815 | Bullish | Relevance: 100%
- The global Edge-GPU Breast Tomosynthesis Box market is projected to grow from $0.47 billion in 2024 to $0.88 billion by 2029, driven by advancements in edge computing, increased government support for diagnostic imaging, and rising breast cancer incidence. North America leads the market, with Asia-Pacific expected to show the fastest growth. Key players include Hologic, GE Healthcare Technologies, and Philips, focusing on enhancing image processing and diagnostic accuracy through strategic acquisitions and technological innovations.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.27M) |
| Sells | 25 ($6.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +1.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.66 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.5x). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.7B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.12 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.66 |
| Forward P/E | 15.0 |
| Current P/E | 16.5 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.7% to 0.1% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.0pp (needs >4.0% for momentum thesis). MRS_5 at 1.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.05% (CS: 38) | Neutral |
| RSI_14 | 66.8 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.144x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $75.00
- **Stop Loss:** $74.24 (1.0% risk)
- **Target:** $75.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1315
- **Position Value:** $98,625.00
- **Portfolio %:** 98.62%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*